Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer

Gonzalez-Angulo, Ana M., Stemke-Hale, Katherine, Palla, Shana L., Carey, Mark, Agarwal, Roshan, Meric-Berstam, Funda, Traina, Tiffany A., Hudis, Clifford, Hortobagyi, Gabriel N., Gerald, William L., Mills, Gordon B., Hennessy, Bryan T.·2009·Clinical Cancer Research

Abstract

Purpose: To examine the androgen receptor (AR) levels in breast cancer and to assess the impact of AR expression on patient outcomes. Experimental Design: Reverse-phase protein arrays were used to measure AR levels and a mass spectroscopy–based approach was used to detect PIK3CA mutations. Means and SDs were generated for AR levels. Linear regression models were used to determine if AR levels differed by tumor subtype and PIK3CA mutation status. Two-sample t tests were used to identify pair-wise differences. Survival probabilities were estimated with the use of the Kaplan-Meier product and log-rank test. Results: The median age was 59 years (23-89 years). Significant differences in AR levels existed among different breast tumor subtypes (highest in estrogen receptor–positive and/or progesterone receptor–positive tumors) as well as by PIK3CA mutation status (P < 0.0001 for both). AR levels were significantly higher in breast tumors with kinase domain PIK3CA mutations versus tumors that are wild type or with PIK3CA helical mutations (P = 0.017 and P < 0.0001, respectively). In 347 patients, dichotomized AR level by the median was a significant prognostic factor of recurrence-free survival (P = 0.0002) and overall survival (P = 0.004). High AR levels were associated with a significantly improved recurrence-free survival in 207 patients with early-stage estrogen/progesterone receptor–positive tumors after adjuvant hormonal therapy. A trend (P = 0.07) was found toward higher AR expression in PIK3CA mutant versus PIK3CA wild-type triple-negative breast tumors. Conclusions: AR levels may represent a prognostic marker in breast cancers and may provide a valuable tool for selecting treatment. There was an association of PIK3CA mutation (kinase domain) with increased AR levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-1763

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 205

Metadata

Authors
Gonzalez-Angulo, A. M., Stemke-Hale, K., Palla, S. L., Carey, M., Agarwal, R., Meric-Berstam, F., Traina, T. A., Hudis, C., Hortobagyi, G. N., Gerald, W. L., Mills, G. B., & Hennessy, B. T.
Venue
Clinical Cancer Research
Published
2009-04-01
Volume
15
Issue
7
Pages
2472-2478
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2146267790
Cited by
205
References
3
FWCI
4.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-1763
The paper
Gonzalez-Angulo, A. M., Stemke-Hale, K., Palla, S. L., Carey, M., Agarwal, R., Meric-Berstam, F., Traina, T. A., Hudis, C., Hortobagyi, G. N., Gerald, W. L., Mills, G. B., & Hennessy, B. T. (2009). Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-1763

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.